APO Research
Talk to an analyst

APO RESEARCH · REPORT

Endometriosis Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Endometriosis Drugs Market Analysis and Forecast 2026-2032

22 December 2025197 pages

Choose your research edition.

Industry ResearchEndometriosis Drugs Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Endometriosis Drugs Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Endometriosis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Endometriosis Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Endometriosis Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Endometriosis Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Endometriosis Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Endometriosis Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Endometriosis Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Endometriosis Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Endometriosis Drugs include Takeda Pharmaceutical Company, Pfizer, AbbVie, AstraZeneca, ValiRx, Roivant Sciences, Repros Therapeutics, ObsEva and Neurocrine Biosciences, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Endometriosis Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Endometriosis Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Endometriosis Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Endometriosis Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Endometriosis Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Endometriosis Drugs revenue, projected growth trends, production technology, application and end-user industry.

Endometriosis Drugs Segment by Company

Takeda Pharmaceutical Company

Pfizer

AbbVie

AstraZeneca

ValiRx

Roivant Sciences

Repros Therapeutics

ObsEva

Neurocrine Biosciences

Kissei Pharmaceutical

Evotec

Debiopharm Group

Astellas Pharma

Endometriosis Drugs Segment by Type

Chinese Herbs

Progestogens

Hormonal Therapy

Add-back Medication

Endometriosis Drugs Segment by Application

Research Institutes

Hospitals

Clinics

Endometriosis Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Endometriosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Endometriosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Endometriosis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Endometriosis Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Endometriosis Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Endometriosis Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Endometriosis Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Chinese Herbs Major Player Table 3. Progestogens Major Player Table 4. Hormonal Therapy Major Player Table 5. Add-back Medication Major Player Table 6. Global Endometriosis Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Research Institutes Major Player Table 8. Hospitals Major Player Table 9. Clinics Major Player Table 10. Endometriosis Drugs Industry Trends Table 11. Endometriosis Drugs Industry Drivers Table 12. Endometriosis Drugs Industry Opportunities and Challenges Table 13. Endometriosis Drugs Industry Restraints Table 14. Global Endometriosis Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Endometriosis Drugs Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Endometriosis Drugs Market Share by Region (2021-2026) Table 17. Global Endometriosis Drugs Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Endometriosis Drugs Market Share by Region (2027-2032) Table 19. Global Endometriosis Drugs Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Endometriosis Drugs Revenue Market Share by Players (2021-2026) Table 21. Global Endometriosis Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Endometriosis Drugs Key Players Headquarters & Area Served Table 23. Global Endometriosis Drugs Players, Product Type & Application Table 24. Global Endometriosis Drugs Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Endometriosis Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Endometriosis Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Endometriosis Drugs Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Endometriosis Drugs Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Endometriosis Drugs Revenue Market Share by Type (2021-2026) Table 31. Global Endometriosis Drugs Revenue Market Share by Type (2027-2032) Table 32. Global Endometriosis Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Endometriosis Drugs Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Endometriosis Drugs Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Endometriosis Drugs Revenue Market Share by Application (2021-2026) Table 36. Global Endometriosis Drugs Revenue Market Share by Application (2027-2032) Table 37. Takeda Pharmaceutical Company Company Information Table 38. Takeda Pharmaceutical Company Business Overview Table 39. Takeda Pharmaceutical Company Endometriosis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Takeda Pharmaceutical Company Endometriosis Drugs Product Portfolio Table 41. Takeda Pharmaceutical Company Recent Development Table 42. Pfizer Company Information Table 43. Pfizer Business Overview Table 44. Pfizer Endometriosis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Pfizer Endometriosis Drugs Product Portfolio Table 46. Pfizer Recent Development Table 47. AbbVie Company Information Table 48. AbbVie Business Overview Table 49. AbbVie Endometriosis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. AbbVie Endometriosis Drugs Product Portfolio Table 51. AbbVie Recent Development Table 52. AstraZeneca Company Information Table 53. AstraZeneca Business Overview Table 54. AstraZeneca Endometriosis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. AstraZeneca Endometriosis Drugs Product Portfolio Table 56. AstraZeneca Recent Development Table 57. ValiRx Company Information Table 58. ValiRx Business Overview Table 59. ValiRx Endometriosis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. ValiRx Endometriosis Drugs Product Portfolio Table 61. ValiRx Recent Development Table 62. Roivant Sciences Company Information Table 63. Roivant Sciences Business Overview Table 64. Roivant Sciences Endometriosis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Roivant Sciences Endometriosis Drugs Product Portfolio Table 66. Roivant Sciences Recent Development Table 67. Repros Therapeutics Company Information Table 68. Repros Therapeutics Business Overview Table 69. Repros Therapeutics Endometriosis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Repros Therapeutics Endometriosis Drugs Product Portfolio Table 71. Repros Therapeutics Recent Development Table 72. ObsEva Company Information Table 73. ObsEva Business Overview Table 74. ObsEva Endometriosis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. ObsEva Endometriosis Drugs Product Portfolio Table 76. ObsEva Recent Development Table 77. Neurocrine Biosciences Company Information Table 78. Neurocrine Biosciences Business Overview Table 79. Neurocrine Biosciences Endometriosis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Neurocrine Biosciences Endometriosis Drugs Product Portfolio Table 81. Neurocrine Biosciences Recent Development Table 82. Kissei Pharmaceutical Company Information Table 83. Kissei Pharmaceutical Business Overview Table 84. Kissei Pharmaceutical Endometriosis Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Kissei Pharmaceutical Endometriosis Drugs Product Portfolio Table 86. Kissei Pharmaceutical Recent Development Table 87. Evotec Company Information Table 88. Evotec Business Overview Table 89. Evotec Endometriosis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Evotec Endometriosis Drugs Product Portfolio Table 91. Evotec Recent Development Table 92. Debiopharm Group Company Information Table 93. Debiopharm Group Business Overview Table 94. Debiopharm Group Endometriosis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Debiopharm Group Endometriosis Drugs Product Portfolio Table 96. Debiopharm Group Recent Development Table 97. Astellas Pharma Company Information Table 98. Astellas Pharma Business Overview Table 99. Astellas Pharma Endometriosis Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Astellas Pharma Endometriosis Drugs Product Portfolio Table 101. Astellas Pharma Recent Development Table 102. North America Endometriosis Drugs Revenue by Type (2021-2026) & (US$ Million) Table 103. North America Endometriosis Drugs Revenue by Type (2027-2032) & (US$ Million) Table 104. North America Endometriosis Drugs Revenue by Application (2021-2026) & (US$ Million) Table 105. North America Endometriosis Drugs Revenue by Application (2027-2032) & (US$ Million) Table 106. North America Endometriosis Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. North America Endometriosis Drugs Revenue by Country (2021-2026) & (US$ Million) Table 108. North America Endometriosis Drugs Revenue by Country (US$ Million) & (2027-2032) Table 109. Europe Endometriosis Drugs Revenue by Type (2021-2026) & (US$ Million) Table 110. Europe Endometriosis Drugs Revenue by Type (2027-2032) & (US$ Million) Table 111. Europe Endometriosis Drugs Revenue by Application (2021-2026) & (US$ Million) Table 112. Europe Endometriosis Drugs Revenue by Application (2027-2032) & (US$ Million) Table 113. Europe Endometriosis Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. Europe Endometriosis Drugs Revenue by Country (2021-2026) & (US$ Million) Table 115. Europe Endometriosis Drugs Revenue by Country (US$ Million) & (2027-2032) Table 116. China Endometriosis Drugs Revenue by Type (2021-2026) & (US$ Million) Table 117. China Endometriosis Drugs Revenue by Type (2027-2032) & (US$ Million) Table 118. China Endometriosis Drugs Revenue by Application (2021-2026) & (US$ Million) Table 119. China Endometriosis Drugs Revenue by Application (2027-2032) & (US$ Million) Table 120. Asia Endometriosis Drugs Revenue by Type (2021-2026) & (US$ Million) Table 121. Asia Endometriosis Drugs Revenue by Type (2027-2032) & (US$ Million) Table 122. Asia Endometriosis Drugs Revenue by Application (2021-2026) & (US$ Million) Table 123. Asia Endometriosis Drugs Revenue by Application (2027-2032) & (US$ Million) Table 124. Asia Endometriosis Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 125. Asia Endometriosis Drugs Revenue by Region (US$ Million) & (2021-2026) Table 126. Asia Endometriosis Drugs Revenue by Region (US$ Million) & (2027-2032) Table 127. SAMEA Endometriosis Drugs Revenue by Type (2021-2026) & (US$ Million) Table 128. SAMEA Endometriosis Drugs Revenue by Type (2027-2032) & (US$ Million) Table 129. SAMEA Endometriosis Drugs Revenue by Application (2021-2026) & (US$ Million) Table 130. SAMEA Endometriosis Drugs Revenue by Application (2027-2032) & (US$ Million) Table 131. SAMEA Endometriosis Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. SAMEA Endometriosis Drugs Revenue by Country (2021-2026) & (US$ Million) Table 133. SAMEA Endometriosis Drugs Revenue by Country (US$ Million) & (2027-2032) Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Endometriosis Drugs Image Figure 2. Global Endometriosis Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Endometriosis Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Chinese Herbs Image Figure 5. Progestogens Image Figure 6. Hormonal Therapy Image Figure 7. Add-back Medication Image Figure 8. Global Endometriosis Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Endometriosis Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 10. Research Institutes Image Figure 11. Hospitals Image Figure 12. Clinics Image Figure 13. Global Endometriosis Drugs Market Size (US$ Million) & (2021-2032) Figure 14. Global Endometriosis Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Endometriosis Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Endometriosis Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Endometriosis Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Endometriosis Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Endometriosis Drugs Revenue Market Share by Type (2021-2032) Figure 21. Global Endometriosis Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Endometriosis Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Endometriosis Drugs Revenue Market Share by Application (2021-2032) Figure 24. North America Endometriosis Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Endometriosis Drugs Revenue Share by Type (2021-2032) Figure 26. North America Endometriosis Drugs Revenue Share by Application (2021-2032) Figure 27. North America Endometriosis Drugs Revenue Share by Country (2021-2032) Figure 28. United States Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Endometriosis Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Endometriosis Drugs Revenue Share by Type (2021-2032) Figure 33. Europe Endometriosis Drugs Revenue Share by Application (2021-2032) Figure 34. Europe Endometriosis Drugs Revenue Share by Country (2021-2032) Figure 35. Germany Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Endometriosis Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Endometriosis Drugs Revenue Share by Type (2021-2032) Figure 45. China Endometriosis Drugs Revenue Share by Application (2021-2032) Figure 46. Asia Endometriosis Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Endometriosis Drugs Revenue Share by Type (2021-2032) Figure 48. Asia Endometriosis Drugs Revenue Share by Application (2021-2032) Figure 49. Asia Endometriosis Drugs Revenue Share by Region (2021-2032) Figure 50. Japan Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Endometriosis Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Endometriosis Drugs Revenue Share by Type (2021-2032) Figure 58. SAMEA Endometriosis Drugs Revenue Share by Application (2021-2032) Figure 59. SAMEA Endometriosis Drugs Revenue Share by Country (2021-2032) Figure 60. Brazil Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Endometriosis Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Chinese Herbs
  • Progestogens
  • Hormonal Therapy
  • Add-back Medication
Applications
  • Research Institutes
  • Hospitals
  • Clinics
Companies covered
  • Takeda Pharmaceutical Company
  • Pfizer
  • AbbVie
  • AstraZeneca
  • ValiRx
  • Roivant Sciences
  • Repros Therapeutics
  • ObsEva
  • Neurocrine Biosciences
  • Kissei Pharmaceutical
  • Evotec
  • Debiopharm Group
  • Astellas Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Endometriosis Drugs Market by Type
  3. 1.2.1 Global Endometriosis Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Chinese Herbs
  5. 1.2.3 Progestogens
  6. 1.2.4 Hormonal Therapy
  7. 1.2.5 Add-back Medication
  8. 1.3 Endometriosis Drugs Market by Application
  9. 1.3.1 Global Endometriosis Drugs Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Research Institutes
  11. 1.3.3 Hospitals
  12. 1.3.4 Clinics
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Endometriosis Drugs Market Dynamics
  1. 2.1 Endometriosis Drugs Industry Trends
  2. 2.2 Endometriosis Drugs Industry Drivers
  3. 2.3 Endometriosis Drugs Industry Opportunities and Challenges
  4. 2.4 Endometriosis Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Endometriosis Drugs Market Perspective (2021-2032)
  2. 3.2 Global Endometriosis Drugs Growth Trends by Region
  3. 3.2.1 Global Endometriosis Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Endometriosis Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Endometriosis Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Endometriosis Drugs Revenue by Players
  2. 4.1.1 Global Endometriosis Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Endometriosis Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Endometriosis Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Endometriosis Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Endometriosis Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Endometriosis Drugs Players, Product Type & Application
  8. 4.5 Global Endometriosis Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Endometriosis Drugs Market CR5 and HHI
  11. 4.6.3 2025 Endometriosis Drugs Tier 1, Tier 2, and Tier 3
5 Endometriosis Drugs Market Size by Type
  1. 5.1 Global Endometriosis Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Endometriosis Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Endometriosis Drugs Revenue Market Share by Type (2021-2032)
6 Endometriosis Drugs Market Size by Application
  1. 6.1 Global Endometriosis Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Endometriosis Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Endometriosis Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda Pharmaceutical Company
  2. 7.1.1 Takeda Pharmaceutical Company Company Information
  3. 7.1.2 Takeda Pharmaceutical Company Business Overview
  4. 7.1.3 Takeda Pharmaceutical Company Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Pharmaceutical Company Endometriosis Drugs Product Portfolio
  6. 7.1.5 Takeda Pharmaceutical Company Recent Developments
  7. 7.2 Pfizer
  8. 7.2.1 Pfizer Company Information
  9. 7.2.2 Pfizer Business Overview
  10. 7.2.3 Pfizer Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Pfizer Endometriosis Drugs Product Portfolio
  12. 7.2.5 Pfizer Recent Developments
  13. 7.3 AbbVie
  14. 7.3.1 AbbVie Company Information
  15. 7.3.2 AbbVie Business Overview
  16. 7.3.3 AbbVie Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 AbbVie Endometriosis Drugs Product Portfolio
  18. 7.3.5 AbbVie Recent Developments
  19. 7.4 AstraZeneca
  20. 7.4.1 AstraZeneca Company Information
  21. 7.4.2 AstraZeneca Business Overview
  22. 7.4.3 AstraZeneca Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 AstraZeneca Endometriosis Drugs Product Portfolio
  24. 7.4.5 AstraZeneca Recent Developments
  25. 7.5 ValiRx
  26. 7.5.1 ValiRx Company Information
  27. 7.5.2 ValiRx Business Overview
  28. 7.5.3 ValiRx Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 ValiRx Endometriosis Drugs Product Portfolio
  30. 7.5.5 ValiRx Recent Developments
  31. 7.6 Roivant Sciences
  32. 7.6.1 Roivant Sciences Company Information
  33. 7.6.2 Roivant Sciences Business Overview
  34. 7.6.3 Roivant Sciences Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Roivant Sciences Endometriosis Drugs Product Portfolio
  36. 7.6.5 Roivant Sciences Recent Developments
  37. 7.7 Repros Therapeutics
  38. 7.7.1 Repros Therapeutics Company Information
  39. 7.7.2 Repros Therapeutics Business Overview
  40. 7.7.3 Repros Therapeutics Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Repros Therapeutics Endometriosis Drugs Product Portfolio
  42. 7.7.5 Repros Therapeutics Recent Developments
  43. 7.8 ObsEva
  44. 7.8.1 ObsEva Company Information
  45. 7.8.2 ObsEva Business Overview
  46. 7.8.3 ObsEva Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 ObsEva Endometriosis Drugs Product Portfolio
  48. 7.8.5 ObsEva Recent Developments
  49. 7.9 Neurocrine Biosciences
  50. 7.9.1 Neurocrine Biosciences Company Information
  51. 7.9.2 Neurocrine Biosciences Business Overview
  52. 7.9.3 Neurocrine Biosciences Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Neurocrine Biosciences Endometriosis Drugs Product Portfolio
  54. 7.9.5 Neurocrine Biosciences Recent Developments
  55. 7.10 Kissei Pharmaceutical
  56. 7.10.1 Kissei Pharmaceutical Company Information
  57. 7.10.2 Kissei Pharmaceutical Business Overview
  58. 7.10.3 Kissei Pharmaceutical Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Kissei Pharmaceutical Endometriosis Drugs Product Portfolio
  60. 7.10.5 Kissei Pharmaceutical Recent Developments
  61. 7.11 Evotec
  62. 7.11.1 Evotec Company Information
  63. 7.11.2 Evotec Business Overview
  64. 7.11.3 Evotec Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Evotec Endometriosis Drugs Product Portfolio
  66. 7.11.5 Evotec Recent Developments
  67. 7.12 Debiopharm Group
  68. 7.12.1 Debiopharm Group Company Information
  69. 7.12.2 Debiopharm Group Business Overview
  70. 7.12.3 Debiopharm Group Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Debiopharm Group Endometriosis Drugs Product Portfolio
  72. 7.12.5 Debiopharm Group Recent Developments
  73. 7.13 Astellas Pharma
  74. 7.13.1 Astellas Pharma Company Information
  75. 7.13.2 Astellas Pharma Business Overview
  76. 7.13.3 Astellas Pharma Endometriosis Drugs Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Astellas Pharma Endometriosis Drugs Product Portfolio
  78. 7.13.5 Astellas Pharma Recent Developments
8 North America
  1. 8.1 North America Endometriosis Drugs Revenue (2021-2032)
  2. 8.2 North America Endometriosis Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Endometriosis Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Endometriosis Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Endometriosis Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Endometriosis Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Endometriosis Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Endometriosis Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Endometriosis Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Endometriosis Drugs Revenue by Country
  11. 8.6.1 North America Endometriosis Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Endometriosis Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Endometriosis Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Endometriosis Drugs Revenue (2021-2032)
  2. 9.2 Europe Endometriosis Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Endometriosis Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Endometriosis Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Endometriosis Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Endometriosis Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Endometriosis Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Endometriosis Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Endometriosis Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Endometriosis Drugs Revenue by Country
  11. 9.6.1 Europe Endometriosis Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Endometriosis Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Endometriosis Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Endometriosis Drugs Revenue (2021-2032)
  2. 10.2 China Endometriosis Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Endometriosis Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Endometriosis Drugs Revenue by Type (2027-2032)
  5. 10.3 China Endometriosis Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Endometriosis Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Endometriosis Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Endometriosis Drugs Revenue by Application (2027-2032)
  9. 10.5 China Endometriosis Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Endometriosis Drugs Revenue (2021-2032)
  2. 11.2 Asia Endometriosis Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Endometriosis Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Endometriosis Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Endometriosis Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Endometriosis Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Endometriosis Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Endometriosis Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Endometriosis Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Endometriosis Drugs Revenue by Country
  11. 11.6.1 Asia Endometriosis Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Endometriosis Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Endometriosis Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Endometriosis Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Endometriosis Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Endometriosis Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Endometriosis Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Endometriosis Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Endometriosis Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Endometriosis Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Endometriosis Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Endometriosis Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Endometriosis Drugs Revenue by Country
  11. 12.6.1 SAMEA Endometriosis Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Endometriosis Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Endometriosis Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst